Elekta: Lowering Our Valuation, Shares Remain Attractive
Elekta refreshed its product lineup, but the turnaround will take longer than we anticipated.
Elekta AB Class B EKTA B
Bulls Say, Bears Say
Bulls
We estimate that the Asia-Pacific marketplace could support up to 5,000 additional linac installations. Given Elekta's strong ties with emerging-market customers, particularly in China, we believe the company can grab a sizable portion of greenfield in this region.
Bears
Unity was Elekta's massive bet, and it is yet to pay off. Advancements in AI could potentially limit the value-add of MR-RT systems, particularly given their significant cost.
Trading Information
- Previous Close Price
- SEK 55.90
- Day Range
- SEK 55.50–56.30
- 52-Week Range
- SEK 41.86–66.70
- Bid/Ask
- SEK 56.05 / SEK 56.15
- Shares Outstanding
- 382.08M
- Market Cap
- SEK 21.51B
- Volume/Avg
- 1M / 1M
Key Statistics
- Price/Earnings (Normalized)
- 15.89
- Price/Sales
- 1.30
- Dividend Yield (Trailing)
- 4.29%
- Dividend Yield (Forward)
- 4.29%
- Dividend Payment Schedule
- Mar, Sep
- Total Yield
- 4.26%
Company Profile
Sweden-based Elekta develops, manufactures, and distributes treatment planning systems for neurosurgery and radiotherapy, including stereotactic radiosurgery and brachytherapy. The company has an installed base of more than 7,300 linear accelerators, Gamma Knife and Unity platforms, as well as brachytherapy installations. The company's sales are evenly distributed across geographies, with North and South America accounting for 27%; Europe, the Middle East, and Africa accounting for 40%; and the Asia-Pacific contributing the remainder.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 3,996
- Website
- https://www.elekta.com
Competitors
Valuation
|
Metric
|
EKTA B
|
SHL
|
BDX
|
|---|---|---|---|
Price/Earnings (Normalized) | 15.89 | 19.26 | 15.42 |
Price/Book Value | 2.84 | 2.44 | 2.24 |
Price/Sales | 1.30 | 2.02 | 2.83 |
Price/Cash Flow | 9.94 | 14.61 | 15.13 |
Price/Earnings
EKTA B
SHL
BDX
Financial Strength
|
Metric
|
EKTA B
|
SHL
|
BDX
|
|---|---|---|---|
Quick Ratio | 0.62 | 0.74 | 0.36 |
Current Ratio | 0.86 | 1.16 | 0.94 |
Interest Coverage | 1.19 | 7.88 | 3.53 |
Quick Ratio
EKTA B
SHL
BDX
Profitability
|
Metric
|
EKTA B
|
SHL
|
BDX
|
|---|---|---|---|
Return on Assets (Normalized) | 1.83% | 5.00% | 4.97% |
Return on Equity (Normalized) | 6.33% | 12.25% | 10.63% |
Return on Invested Capital (Normalized) | 5.06% | 12.99% | 7.26% |
Return on Assets
EKTA B
SHL
BDX
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|%M^$Xx | LOCK|NHT< | $177B | |||
| Medtronic PLC
MDT
| LOCK|<>FzRs | LOCK|<&zj | $124B | |||
| Stryker Corp
SYK
| LOCK|$^ff#S&# | LOCK|qf | $118B | |||
| Boston Scientific Corp
BSX
| LOCK|?d>dp^w | LOCK|&&Lp@ | $67B | |||
| Edwards Lifesciences Corp
EW
| LOCK|?KpYJ%bx | LOCK|GQ!%r | $52B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|@<^HwM^ | LOCK|Zx | $32B | |||
| DexCom Inc
DXCM
| LOCK|Mj$FLw< | LOCK|fbyf> | $30B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|Qs> | LOCK|#qR | $26B | |||
| Steris PLC
STE
| LOCK|^<&T&sp | LOCK|m&N# | $23B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|LB>s?JKv | LOCK|j@j | $19B |
United States